COSM LOI to buy Doc Pharma — adds GMP plant and ~$24M in assets
AI Summary
Cosmos Health (NASDAQ: COSM) signed a non-binding LOI to acquire 100% of Doc Pharma S.A., a European GMP-certified pharmaceutical manufacturer with an ~59,000 sq ft production facility, multiple certifications (GMP/ISO/Kosher/Halal) and approvals for several Middle East markets. The company says the deal would be immediately accretive — Doc Pharma's three‑year averages are ~ $24M in assets, ~$6.7M annual revenue and ~$3.2M annual gross profit — and would deepen vertical integration, expand dosage-form capabilities, and broaden Cosmos's branded generics/OTC portfolio. The target is a related party, so the transaction requires independent committee review, a fairness opinion, a PCAOB audit, shareholder approval and final due diligence; completion is not guaranteed.
Positives
- Adds GMP-certified ~59,000 sq ft manufacturing facility with broad dosage-form capabilities
- Brings ~ $24M in assets and three-year average annual revenue of ~$6.7M and gross profit of ~$3.2M — company expects immediate accretion
- Expands in-house product portfolio (advanced/branded generics and OTC) and regulatory registrations for markets including UAE, Qatar, Iraq and Lebanon
Negatives
- LOI is non-binding and the transaction is subject to due diligence — completion not guaranteed
- This is a related-party deal requiring independent committee review, a fairness opinion, PCAOB audit and shareholder approval
- Financial figures are three-year averages converted from euros and subject to final verification